198 related articles for article (PubMed ID: 16644201)
41. Cutting edge: rapid accumulation of epidermal CCL27 in skin-draining lymph nodes following topical application of a contact sensitizer recruits CCR10-expressing T cells.
Huang V; Lonsdorf AS; Fang L; Kakinuma T; Lee VC; Cha E; Zhang H; Nagao K; Zaleska M; Olszewski WL; Hwang ST
J Immunol; 2008 May; 180(10):6462-6. PubMed ID: 18453562
[TBL] [Abstract][Full Text] [Related]
42. [Expression of galanin in melanocytic tumors].
Gilaberte Y; Vera J; Coscojuela C; Roca MJ; Parrado C; González S
Actas Dermosifiliogr; 2007; 98(1):24-34. PubMed ID: 17374330
[TBL] [Abstract][Full Text] [Related]
43. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
44. CCR10 and its ligands in regulation of epithelial immunity and diseases.
Xiong N; Fu Y; Hu S; Xia M; Yang J
Protein Cell; 2012 Aug; 3(8):571-80. PubMed ID: 22684736
[TBL] [Abstract][Full Text] [Related]
45. Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma.
Torisu-Itakura H; Lee JH; Scheri RP; Huynh Y; Ye X; Essner R; Morton DL
Clin Cancer Res; 2007 Jun; 13(11):3125-32. PubMed ID: 17545514
[TBL] [Abstract][Full Text] [Related]
46. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
Kuźbicki L; Gajo B; Chwirot BW
Melanoma Res; 2006 Jun; 16(3):235-43. PubMed ID: 16718270
[TBL] [Abstract][Full Text] [Related]
47. CCR10 activation stimulates the invasion and migration of breast cancer cells through the ERK1/2/MMP-7 signaling pathway.
Lin HY; Sun SM; Lu XF; Chen PY; Chen CF; Liang WQ; Peng CY
Int Immunopharmacol; 2017 Oct; 51():124-130. PubMed ID: 28830025
[TBL] [Abstract][Full Text] [Related]
48. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients.
Campillo JA; Martínez-Escribano JA; Moya-Quiles MR; Marín LA; Muro M; Guerra N; Parrado A; Campos M; Frías JF; Minguela A; García-Alonso AM; Alvarez-López MR
Clin Cancer Res; 2006 Aug; 12(16):4822-31. PubMed ID: 16914567
[TBL] [Abstract][Full Text] [Related]
49. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.
Karim RZ; Li W; Sanki A; Colman MH; Yang YH; Thompson JF; Scolyer RA
Int J Surg Pathol; 2009 Oct; 17(5):361-7. PubMed ID: 19666944
[TBL] [Abstract][Full Text] [Related]
50. Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2).
Wang W; Soto H; Oldham ER; Buchanan ME; Homey B; Catron D; Jenkins N; Copeland NG; Gilbert DJ; Nguyen N; Abrams J; Kershenovich D; Smith K; McClanahan T; Vicari AP; Zlotnik A
J Biol Chem; 2000 Jul; 275(29):22313-23. PubMed ID: 10781587
[TBL] [Abstract][Full Text] [Related]
51. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
[TBL] [Abstract][Full Text] [Related]
52. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
53. HLA-G expression in malignant melanoma.
Rebmann V; Wagner S; Grosse-Wilde H
Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098
[TBL] [Abstract][Full Text] [Related]
54. Arginine metabolism in tumor-associated macrophages in cutaneous malignant melanoma: evidence from human and experimental tumors.
Massi D; Marconi C; Franchi A; Bianchini F; Paglierani M; Ketabchi S; Miracco C; Santucci M; Calorini L
Hum Pathol; 2007 Oct; 38(10):1516-25. PubMed ID: 17640716
[TBL] [Abstract][Full Text] [Related]
55. The chemokine receptor D6 limits the inflammatory response in vivo.
Jamieson T; Cook DN; Nibbs RJ; Rot A; Nixon C; McLean P; Alcami A; Lira SA; Wiekowski M; Graham GJ
Nat Immunol; 2005 Apr; 6(4):403-11. PubMed ID: 15750596
[TBL] [Abstract][Full Text] [Related]
56. Effect of melanoma on immune function in the regional lymph node basin.
Negin B; Panka D; Wang W; Siddiqui M; Tawa N; Mullen J; Tahan S; Mandato L; Polivy A; Mier J; Atkins M
Clin Cancer Res; 2008 Feb; 14(3):654-9. PubMed ID: 18245524
[TBL] [Abstract][Full Text] [Related]
57. The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors.
Nibbs RJ; Gilchrist DS; King V; Ferra A; Forrow S; Hunter KD; Graham GJ
J Clin Invest; 2007 Jul; 117(7):1884-92. PubMed ID: 17607362
[TBL] [Abstract][Full Text] [Related]
58. [Is there a novel subset of Th22 lymphocytes in the skin distinct from Th17 lymphocytes?].
Yssel H; Bensussan A
Med Sci (Paris); 2010 Jan; 26(1):12-4. PubMed ID: 20132763
[No Abstract] [Full Text] [Related]
59. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
Gambichler T; Rotterdam S; Radkowski K; Altmeyer P; Kreuter A
Am J Clin Pathol; 2009 May; 131(5):710-4. PubMed ID: 19369632
[TBL] [Abstract][Full Text] [Related]
60. Oestrogen receptor-beta expression in melanocytic lesions.
Schmidt AN; Nanney LB; Boyd AS; King LE; Ellis DL
Exp Dermatol; 2006 Dec; 15(12):971-80. PubMed ID: 17083364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
